US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2014 Status changed from recruiting to active, no longer recruiting based on information reported in a DATA BioSciences media release.
13 Mar 2014 Results will be presented at the National Comprehensive Cancer Network (NCCN) 19th Annual Conference: Advancing the Standard of Cancer Care according to a DARA BioSciences media release. Results were also reported in the media release.
14 Aug 2013 DARA BioSciences has enrolled 13 US oncology centres and completed nearly 50% of the patient surveys in this registry, according to a company media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com